Grandfield & Dodd, LLC Biomarin Pharmaceutical Inc Transaction History
Grandfield & Dodd, LLC
- $1.53 Billion
- Q4 2024
A detailed history of Grandfield & Dodd, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 17,392 shares of BMRN stock, worth $1.24 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
17,392
Previous 16,661
4.39%
Holding current value
$1.24 Million
Previous $1.17 Million
2.39%
% of portfolio
0.07%
Previous 0.07%
Shares
30 transactions
Others Institutions Holding BMRN
# of Institutions
627Shares Held
183MCall Options Held
2MPut Options Held
1.67M-
Black Rock Inc. New York, NY22.7MShares$1.62 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.38 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.3 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$1.05 Billion0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$928 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $13.3B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...